Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo

Cancer Letters

Volumn 279, Issue 2, 2009, Pages 213-220

  Li, Jing ^a   Li, Yan ^a   Feng, Zhi qiang ^a   Chen, Xiao guang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

EGFR; F90; Gefitinib; Non small cell lung cancer; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; F 90; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; N (3 CHLORO 4 FLUOROPHENYL) N [7 METHOXY 6 (3 MORPHOLINOPROPOXY)QUINAZOLIN 4 YL] 3,3 DIMETHYLBUTANAMIDE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS;

MUS MUSCULUS;

EID: 67349168708     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.01.042     Document Type: Article

References (24)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., and Thun M.J. Cancer statistics. CA Cancer J. Clin. 56 (2006) 106-130
2. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., Zhu J., and Johnson D.H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl. J. Med. 346 (2002) 92-98
3. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., and Bemis L. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97 9 (2005) 643-655
4. Yarden Y. The EGFR family and its ligands in human cancer signaling mechanisms and therapeutic opportunities. Eur. J. Cancer 37 Suppl. 4 (2001) S3-8
5. Janmaat M.L., and Giaccone G. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today 39 Suppl. C (2003) 61-80
6. Noro R., Gemma A., Kosaihira S., Kokubo Y., Chen M., Seike M., Kataoka K., Matsuda K., Okano T., Minegishi Y., Yoshimura A., and Kudoh S. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. BMC Cancer 6 (2006) 277
7. Auberger J., Loeffler-Ragg J., Wurzer W., and Hilbe W. Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises. Curr. Cancer Drug Targets 6 (2006) 271-294
8. Prenzel N., Fischer O.M., Streit S., Hart S., and Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer 8 (2001) 11-31
9. Herbst R.S., and Bunn Jr. P.A. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin. Cancer Res. 9 16 Pt 1 (2003) 5813-5824
10. Ciardiello F., De Vita F., Orditura M., and Tortora G. The role of EGFR inhibitors in nonsmall cell lung cancer. Curr. Opin. Oncol. 16 2 (2004) 130-135
11. Janne P.A., Taffaro M.L., Salgia R., and Johnson B.E. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 62 (2002) 5242-5247
12. Kim E.S., R Khuri F., and Herbst R.S. Epidermal growth factor receptor biology (IMC-C225). Curr. Opin. Oncol. 13 6 (2001) 506-513
13. Mendelsohn J., and Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21 (2003) 2787-2799
14. Harichand-Herdt S., and Ramalingam S.S. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor. Semin. Thorac. Cardiovasc. Surg. 20 3 (2008) 217-223
15. Miller V.A., Johnson D.H., Krug L.M., Pizzo B., Tyson L., Perez W., Krozely P., Sandler A., Carbone D., and Heelan R.T. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lune cancer. J. Clin. Oncol. 21 (2003) 2094-2100
16. Miller V.A., Kris M.G., Shah N., Patel J., Azzoli C., Gomez J., Krug L.M., Pao W., Rizvi N., and Pizzo B. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J. Clin. Oncol. 22 (2004) 1103-1109
17. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., and Haluska F.G. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl. J. Med. 350 (2004) 2129-2139
18. Gridelli C., Maione P., Galetta D., Colantuoni G., Del Gaizo F., Ferrara C., Guerriero C., Nicolella D., and Rossi A. Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. J. Thorac. Oncol. 2 (2007) 758-761
19. Choong N.W., Dietrich S., Seiwert T.Y., Tretiakova M.S., Nallasura V., Davies G.C., Lipkowitz S., Husain A.N., Salgia R., and Ma P.C. Gefitinib response of erlotinib-refractory lung cancer involving meninges-role of EGFR mutation. Nat. Clin. Pract. Oncol. 3 (2006) 50-57
20. Cho B.C., Im C.K., Park M.S., Kim S.K., Chang J., Park J.P., Choi H.J., Kim Y.J., Shin S.J., and Sohn J.H. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J. Clin. Oncol. 25 (2007) 2528-2533
21. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., Nishiwaki Y., Vansteenkiste J., Kudoh S., and Rischin D. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 21 (2003) 2237-2246
22. Felip E., and Rosell R. Clinical experience with erlotinib in non-small-cell lung cancer. Drugs Today (Barc.) 42 3 (2006) 147-156
23. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., Campos D., Maoleekoonpiroj S., Smylie M., and Martins R. Erlotinib in previously treated non-small-cell lung cancer. New Engl. J. Med. 353 (2005) 123-132
24. Ciardiello F., and Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7 (2001) 2958-2970